Académique Documents
Professionnel Documents
Culture Documents
artery disease
23
Hypertension and CAD
* EF ≤40%
23
Hypertension and HFrEF
fibrillation
23
Hypertension and atrial
fibrillation
DM = diabetes mellitus
TIA = transient ischemic attack
PAD = peripheral artery disease
HMOD = hypertension mediated organ damage
21
PREFERRED DRUGS
kidney disease
23
Hypertension and CKD
7
Comparative Incidence of New-Onset
Diabetes with Antihypertensive Agents in Clinical Trials
Study Treatments Duration New-onset P-value
(years) diabetes (%)
CAPP ACE-I vs 6.1 6.5 vs 7.3 <0.05
-blocker/diuretic
10 Atenolol-based regimen
Proportion of new-onset diabetes
Amlodipine-based regimen
8
2 HR 0.70
mellitus
p<0.0001
0
0 1 2 3 4 5 6
Time (years)
Asymptomatic
• •
atherosclerosis
Microalbuminuria
• •
LVH • • •
ISH (elderly)
• •
Mets • • •
Pregnancy CCB, ß-blocker (labetolol), methyldopa
Mancia G, et al. 2007 ESH/ESC Guidelines for the Management of Arterial Hypertension.
J Hypertens 2007;25:1105-1187
11
BRIDGING THE GAP
13
Distribution of Adrenoceptors and The Physiologic Effects of Stimulation
Predominant
Organ Physiological effect of stimulation
adrenoceptor
1 Vasodilatation (coronary)
Smooth muscle: blood vessels
2 Vasodilatation
75/1
1/2 Selectivity Ratios
35/1 35/1
20/1
1/2
-1/50
-1/300
ICI
118,551
17
TAKE-HOME MESSAGE
Despite its potential effect on the development
of new-onset diabetes, betablockers may be
used in most hypertension patients with
cardiac diseases. Therefore, choosing a best
betablocker is required.